1. Show article details.

    China's Henlius raises $410 million in Hong Kong IPO-sources

    Reuters – 5:59 AM ET 09/18/2019

    * Prices shares at HK$49.6 apiece. * Hong Kong IPO activity picking up after difficult summer. By Julie Zhu and Scott Murdoch. Shanghai Henlius Biotech has raised $410 million after pricing its Hong Kong initial public offering at the bottom end of the indicative pricing range, two people with direct knowledge of the matter said on Wednesday.

  2. Show article details.

    Amgen Showcases New Data From Oncology Pipeline And Portfolio At ESMO 2019

    PR Newswire – 4:00 PM ET 09/17/2019

    THOUSAND OAKS, Calif. Clinical data presentations will include a poster discussion on the ongoing Phase 1 trial of AMG 510, highlighting responses in KRAS G12C-mutant solid tumors, including patients with advanced non-small cell lung, colorectal and appendiceal cancers.

  3. Show article details.

    BRIEF-Adaptive Biotechnologies Enters Partnership For Use Of Clonoseq As Preferred MRD Test For Drug Development Across Amgen’s Hematology Franchise

    Reuters – 8:34 AM ET 09/17/2019

    Adaptive Biotechnologies Corp (ADPT): * ADAPTIVE BIOTECHNOLOGIES ENTERS PARTNERSHIP FOR USE OF CLONOSEQ® AS PREFERRED MRD TEST FOR DRUG DEVELOPMENT ACROSS AMGEN’S HEMATOLOGY FRANCHISE. * Adaptive Biotechnologies Corp (ADPT) - HAS ENTERED INTO A FOUR-YEAR GLOBAL AGREEMENT WITH AMGEN Source text for Eikon: Further company coverage:

  4. Show article details.

    S&P 500 buybacks decline significantly in Q2 2019; expenditures still remain higher than the pre-2018 levels

    PR Newswire – 11:30 AM ET 09/16/2019

    NEW YORK, Sept. 16, 2019 S&P Dow Jones Indices announced today that preliminary Q2 2019 S&P 500® stock buybacks, or share repurchases, were $164.5 billion. This was the second consecutive quarterly decline after four consecutive quarters of record buybacks. Historical data on S&P 500 buybacks are available at www.spdji.com/indices/equity/sp-500.

  5. Show article details.

    Amgen To Present At The Bank of America Merrill Lynch Global Healthcare Conference

    PR Newswire – 4:00 PM ET 09/13/2019

    THOUSAND OAKS, Calif. About AmgenAmgen (AMGN) is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. Amgen (AMGN) focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives.

  6. Show article details.

    Biogen scraps two late-stage trials for Alzheimer's treatment

    Reuters – 12:09 PM ET 09/13/2019

    Biogen Inc (BIIB) and Eisai Co Ltd (ESALF) are abandoning two late-stage trials for their Alzheimer's treatment in a widely anticipated move that comes months after the companies scrapped trials of another drug for the memory-robbing disease.

  7. Show article details.

    BRIEF-Amgen Announces Phase 3 Candor Study Combining Kyprolis And Darzalex Meets Primary Endpoint Of Progression-Free Survival

    Reuters – 9:34 AM ET 09/13/2019

    Amgen Inc (AMGN): * AMGEN ANNOUNCES PHASE 3 CANDOR STUDY COMBINING KYPROLIS® AND DARZALEX® MEETS PRIMARY ENDPOINT OF PROGRESSION-FREE SURVIVAL. * Amgen Inc (AMGN) - THERE WAS A HIGHER FREQUENCY OF ADVERSE EVENTS REPORTED IN KDD, A THREE-AGENT REGIMEN, THAN IN KD, A TWO-AGENT REGIMEN.

  8. Show article details.

    Amgen Announces Phase 3 CANDOR Study Combining KYPROLIS® (carfilzomib) And DARZALEX® (daratumumab) Meets Primary Endpoint Of Progression-Free Survival

    PR Newswire – 9:00 AM ET 09/13/2019

    THOUSAND OAKS, Calif. "The potential to combine KYPROLIS with DARZALEX, two powerful targeted agents, represents an additional therapeutic approach for patients with relapsed or refractory multiple myeloma," said David M. Reese, M.D., executive vice president of Research and Development at Amgen.

  9. Show article details.

    BRIEF-Amgen Highlights New Data From Kyprolis (Carfilzomib) And Oncology Pipeline At IMW 2019

    Reuters – 9:17 AM ET 09/12/2019

    Amgen Inc (AMGN): * AMGEN HIGHLIGHTS NEW DATA FROM KYPROLIS® AND ONCOLOGY PIPELINE AT IMW 2019. * Amgen Inc (AMGN) - DATA PRESENTED FROM ANTI-BCMA BITE® AND MCL-1 PROGRAMS. * Amgen Inc (AMGN) - A PHASE 1 DOSE ESCALATION STUDY OF AMG 701 IS UNDERWAY WITH DATA EXPECTED FOR PRESENTATION IN 2020.

  10. Show article details.

    Amgen Highlights New Data From KYPROLIS® (carfilzomib) And Oncology Pipeline At IMW 2019

    PR Newswire – 9:00 AM ET 09/12/2019

    THOUSAND OAKS, Calif. Data featured from Amgen's (AMGN) hematology franchise will include oral presentations from Phase 1 studies of AMG 420, the anti-B-cell maturation antigen bispecific T cell engager and AMG 176, the MCL-1 inhibitor in patients with relapsed or refractory multiple myeloma.

  11. Show article details.

    deCODE in Iceland Agrees to Sequence Half of UK Biobanks Participants

    PR Newswire – 11:49 AM ET 09/11/2019

    REYKJAVIK, Iceland, Sept. 11, 2019  deCODE genetics in Iceland has entered into an agreement with a consortium of government, charity, researchers and world leading biopharmaceutical and healthcare companies to undertake whole genome sequencing of UK Biobank participants. The UK Biobank is an extraordinary resource for medical research that Great Britain has built over the past 15 years.

  12. Show article details.

    Henlius Biotech launches $477 mln HK IPO, testing market amid protests

    Reuters – 9:41 PM ET 09/10/2019

    * First sizeable IPO to test market sentiment amid HK's protests. * Henlius sets IPO price range at HK$49.6 to HK$57.8 -term sheet. * Company valued at $3 bln to $3.5 bln prior to IPO -term sheet. * Qatar Investment Authority is biggest cornerstone -term sheet. By Julie Zhu.

  13. Amgen stock price target raised to $198 from $191 at J.P. Morgan

    MarketWatch – 7:41 AM ET 09/10/2019
  14. Show article details.

    US STOCKS-Wall St ends flat amid rate hopes, tech declines

    Reuters – 4:37 PM ET 09/09/2019

    * AT&T (T) rises after activist Elliott urges asset sales. * Technology, healthcare indexes fall. * Dow up 0.1%, S&P 500 down 0.01%, Nasdaq off 0.2% By Caroline Valetkevitch. NEW YORK, Sept 9 - U.S. stocks ended flat on Monday as increased expectations of stimulus from central banks around the world were offset by losses in technology and healthcare shares.

  15. Show article details.

    US STOCKS-Tech, healthcare weigh on Wall Street, stimulus hopes flicker

    Reuters – 1:38 PM ET 09/09/2019

    * AT&T (T) jumps after activist Elliott urges asset sales. * U.S. 10-yr, 30-yr yields hit three-week highs. * Technology top drag among S&P sectors. * Dow up 0.08%, S&P 500 down 0.08%, Nasdaq off 0.28% By Uday Sampath Kumar.

  16. Show article details.

    US STOCKS-Stimulus hopes buoy Wall Street, financials lead gains

    Reuters – 12:15 PM ET 09/09/2019

    * AT&T (T) jumps after activist Elliott urges asset sales. * U.S. 10-yr, 30-yr yields hit three-week highs. * Healthcare top drag among S&P sectors. * Indexes up: Dow 0.26%, S&P 500 0.12%, Nasdaq 0.09% By Uday Sampath Kumar. Sept 9 - Wall Street's main indexes edged higher on Monday as investors bet on increased chances of monetary stimulus from central banks around the world to boost slowing growth.

  17. Show article details.

    US STOCKS-Stimulus hopes lift Wall Street, financial stocks lead gains

    Reuters – 10:58 AM ET 09/09/2019

    * AT&T (T) jumps after activist Elliott urges asset sales. * Healthcare top drag among S&P sectors. * U.S. 10-yr, 30-yr yields hit three-week highs. * Dow up 0.32%, S&P 500 up 0.17%, Nasdaq off 0.04% By Uday Sampath Kumar.

  18. Show article details.

    US STOCKS-Wall Street set to open higher on hopes of monetary stimulus

    Reuters – 9:17 AM ET 09/09/2019

    * Futures up: Dow 0.23%, S&P 0.34%, Nasdaq 0.29% By Uday Sampath Kumar. U.S. stocks were set to open higher on Monday, as mixed global economic data lifted expectations of monetary stimulus from central banks, including the U.S. Federal Reserve.

  19. Show article details.

    BRIEF- Toronto Innovation Acceleration Partners Announces Strategic Partnership With Amgen

    Reuters – 7:21 AM ET 09/09/2019

    Toronto Innovation Acceleration Partners: * TIAP-AMGEN & TIAP WILL JOINTLY FUND NASCENT TECHNOLOGIES MANAGED BY TIAP ON BEHALF OF TORONTO-BASED MEMBER INSTITUTIONS. * TORONTO INNOVATION ACCELERATION PARTNERS ANNOUNCES STRATEGIC PARTNERSHIP WITH AMGEN.

  20. Show article details.

    US STOCKS-Futures edge higher on hopes of monetary stimulus

    Reuters – 7:21 AM ET 09/09/2019

    * Futures up: Dow 0.20%, S&P 500 0.24%, Nasdaq 0.21% By Uday Sampath Kumar. U.S. stock index futures ticked higher on Monday, as mixed global economic data drove expectations of monetary stimulus from central banks, including the U.S. Federal Reserve.

Page:

Today's and Upcoming Events

  • Oct
    28

    AMGN to announce Q3 earnings (Unconfirmed)

Past Events (last 90 days)

  • Aug
    14

    AMGN ex-Dividend for $1.45 on 08/14/2019

    • Announce Date: 08/02/2019
    • Record Date: 08/15/2019
    • Pay Date: 09/06/2019
  • Jul
    30

    AMGN announced Q2 earnings.

Data provided by Thomson Reuters © 2019

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.

462499.6.0
See the Latest Features
Personalized
Get relevant information about your holdings right when you need it.
See Your Performance Click the portfolio icon to get information about stocks you own without leaving the research page.
Faster Access to Positions A shortcut to view the full list of positions in your portfolio? Yes, please! Use the ticker search box.
Add Your Own Notes Use Notebook to save your investment ideas in one convenient, private, and secure place.
Convenient For You
Research that's clear, accessible, and all in one place makes for a better experience.
One-Stop Shop See everything you need to make investment decisions right in the dashboard.
Access Anywhere No matter where you are, use the Stock Research experience across multiple devices.
New Ideas, On the Ready Find new ideas using quick links to the Stock Screener.
New Ways to Research
Discover new tools to add or diversify your existing research strategy.
StockTwits Read live tweets from the financial and investing community about the stock you're interested in.
Fundamental Analysis Save time on research by getting an overall assessment of a company's valuation, quality, growth stability, and financial health.
Recognia Technical Analysis Perfect for the technical trader—this indicator captures a stock's technical events and converts them into short, medium, and long-term sentiment.
Top Competitors See how a stock measures up by instantly comparing it to the industry average and its top four competitors.
Social Sentiment Get a sense of people's overall feelings towards a company in social media with this summary tool.
Earnings Data Monitor earnings expectations over the past three quarters and model a stock's price based on its P/E.